Laura C Rosella, Mackenzie Hurst, Emmalin Buajitti, Thomas Samson, L Trevor Young, Ana C Andreazza
{"title":"A population-based cohort study of mitochondrial disease and mental health conditions in Ontario, Canada.","authors":"Laura C Rosella, Mackenzie Hurst, Emmalin Buajitti, Thomas Samson, L Trevor Young, Ana C Andreazza","doi":"10.1186/s13023-025-03688-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Mitochondrial disease has been linked to mental health disorder in clinical cohorts and post-mortem studies. However, a lack of population-level studies examining the relationship between mitochondrial disease and mental health has resulted in an evidence gap and creates a challenge for identifying and addressing care needs for the mitochondrial disease population. Using multiple linked population health databases in a single-payer health system that covers the full population, this study aimed to investigate the prevalence of mood disorders and other mental health conditions in patients with mitochondrial disease and to examine the joint impact of mitochondrial disease and mental health conditions on healthcare use and health system costs. To contextualize these findings, a clinical comparator cohort of multiple sclerosis (MS) patients was analyzed.</p><p><strong>Results: </strong>Overall, co-prevalent mental health conditions are common in the mitochondrial population. Double the proportion of patients in the mitochondrial disease cohort had a co-prevalent mental health illness as compared to the MS population (18% vs 9%). Healthcare utilization was highest among patients with co-prevalent mitochondrial disease and mental illness, with 49% hospitalized within 1 year prior to cohort entry (compared to 12% of MS patients with no mental health condition). Costs were likewise highest among mitochondrial disease patients with mental health conditions.</p><p><strong>Conclusions: </strong>This study presents the first comprehensive, population-wide cohort study of mitochondrial disease and co-prevalent mental health conditions. Our findings demonstrate a high burden of mental health conditions among mitochondrial disease patients, with high associated health care needs. We also find that patients with concurrent mental illness and mitochondrial disease represent a high-burden, high-cost population in a single-payer health insurance setting.</p>","PeriodicalId":19651,"journal":{"name":"Orphanet Journal of Rare Diseases","volume":"20 1","pages":"177"},"PeriodicalIF":3.4000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11995528/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orphanet Journal of Rare Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13023-025-03688-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Mitochondrial disease has been linked to mental health disorder in clinical cohorts and post-mortem studies. However, a lack of population-level studies examining the relationship between mitochondrial disease and mental health has resulted in an evidence gap and creates a challenge for identifying and addressing care needs for the mitochondrial disease population. Using multiple linked population health databases in a single-payer health system that covers the full population, this study aimed to investigate the prevalence of mood disorders and other mental health conditions in patients with mitochondrial disease and to examine the joint impact of mitochondrial disease and mental health conditions on healthcare use and health system costs. To contextualize these findings, a clinical comparator cohort of multiple sclerosis (MS) patients was analyzed.
Results: Overall, co-prevalent mental health conditions are common in the mitochondrial population. Double the proportion of patients in the mitochondrial disease cohort had a co-prevalent mental health illness as compared to the MS population (18% vs 9%). Healthcare utilization was highest among patients with co-prevalent mitochondrial disease and mental illness, with 49% hospitalized within 1 year prior to cohort entry (compared to 12% of MS patients with no mental health condition). Costs were likewise highest among mitochondrial disease patients with mental health conditions.
Conclusions: This study presents the first comprehensive, population-wide cohort study of mitochondrial disease and co-prevalent mental health conditions. Our findings demonstrate a high burden of mental health conditions among mitochondrial disease patients, with high associated health care needs. We also find that patients with concurrent mental illness and mitochondrial disease represent a high-burden, high-cost population in a single-payer health insurance setting.
背景:在临床队列和死后研究中,线粒体疾病与精神健康障碍有关。然而,由于缺乏对线粒体疾病与精神健康之间关系的人口水平研究,导致证据不足,并为确定和解决线粒体疾病人群的护理需求带来了挑战。本研究使用覆盖全部人口的单一付款人健康系统中的多个关联人口健康数据库,旨在调查线粒体疾病患者情绪障碍和其他精神健康状况的患病率,并检查线粒体疾病和精神健康状况对医疗保健使用和卫生系统成本的共同影响。为了对这些发现进行背景分析,我们对多发性硬化症(MS)患者的临床比较队列进行了分析。结果:总体而言,共同流行的精神健康状况在线粒体人群中很常见。线粒体疾病队列患者同时患有精神健康疾病的比例是多发性硬化症人群的两倍(18% vs 9%)。在线粒体疾病和精神疾病共同流行的患者中,医疗保健利用率最高,49%的患者在队列进入前1年内住院(相比之下,没有精神健康状况的MS患者为12%)。同样,患有线粒体疾病的精神健康状况患者的费用最高。结论:这项研究提出了线粒体疾病和共同流行的精神健康状况的第一个全面的、全人群的队列研究。我们的研究结果表明,线粒体疾病患者的精神健康状况负担高,相关的医疗保健需求高。我们还发现,同时患有精神疾病和线粒体疾病的患者在单一付款人的健康保险环境中是一个高负担、高成本的人群。
期刊介绍:
Orphanet Journal of Rare Diseases is an open access, peer-reviewed journal that encompasses all aspects of rare diseases and orphan drugs. The journal publishes high-quality reviews on specific rare diseases. In addition, the journal may consider articles on clinical trial outcome reports, either positive or negative, and articles on public health issues in the field of rare diseases and orphan drugs. The journal does not accept case reports.